Olympus recently announced its SeleCT Connect program, which uses diagnostic imaging AI to automatically screen which people might benefit from its Spiration valve system.
Spiration is an FDA-designated breakthrough device for treating chronic obstructive pulmonary disease (COPD) patients.
SeleCT Connect — offered as part of Olympus’ SeleCT quantitative computer tomography (QCT) analysis service — is available immediately to more than 9,000 U.S. healthcare through the Nuance AI Marketplace, a workflow-integrated cloud platform for diagnostic imaging AI algorithms.
Nuance Communications, which Microsoft is acquiring, and Olympus’ AI-based SeleCT analysis partner Imbio helped create the SeleCT Connect program.
SeleCT Connect automatically sends CT studies directly from physicians and radiologists’ picture archive and communication system (PACS) to the SeleCT QCT analysis service. Results automatically return to the patient record following analysis. The new service also allows SeleCT analysis results to be sent to a health system’s electronic health record (EHR) for easier referring physician access.
“The connection to Nuance’s expansive network of healthcare facilities helps physicians to quickly and easily identify qualified patients for key interventional respiratory procedures,” Lynn Ray, global GM and VP of Respiratory for Olympus, said in a July 27 news release. “Using automated workflows, this solution enables treating physicians’ access to detailed diagnostic data from the Imbio AI imaging solutions to determine if COPD patients can take advantage of our breakthrough Spiration Valve therapy, which has been shown to improve quality of life for qualified patients.”